.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
A major trial published in the New England Journal of Medicine demonstrates that sirolimus-coated balloon angioplasty effectively reduces the incidence of major adverse limb events in patients with infrainguinal artery disease. These findings from the SirPAD trial represent a significant shift in the endovascular management of peripheral arterial conditions worldwide. Given the high burden of peripheral artery disease in India, specifically among patients with diabetes, this evidence provides a vital upgrade to current treatment protocols.
The study enrolled 1,252 patients across multiple centers to compare clinical outcomes. Specifically, researchers randomly assigned participants to receive either a sirolimus-coated balloon or a standard uncoated balloon. They primarily aimed to evaluate the composite rate of unplanned major amputation or target lesion revascularization for critical limb ischemia within one year. Consequently, the results provide high-quality evidence for clinical decision-making in vascular interventions.
The sirolimus-coated group showed a significantly lower primary-outcome rate of 8.8% compared to 15.0% in the uncoated group. Additionally, the statistical analysis confirmed the superiority of the drug-coated platform with a significant p-value of 0.009. Therefore, this technology offers a robust solution for maintaining vessel patency. Moreover, the safety profile was very reassuring for practitioners. There were no significant differences in all-cause mortality between the two groups. As a result, clinicians can confidently adopt this technique without increased safety concerns.
In contrast to previous studies using different drugs, sirolimus acts as a cytostatic agent. It effectively inhibits neointimal hyperplasia after the initial procedure. Furthermore, this approach minimizes the need for repeated interventions. Similarly, it reduces the risk of limb loss in vulnerable patient populations. However, practitioners must ensure proper vessel preparation to optimize drug transfer. Overall, the trial reinforces the role of advanced balloon technologies in modern practice.
The primary outcome was a composite of unplanned major amputation or revascularization of the target lesion for critical limb ischemia within one year. The trial found that sirolimus-coated balloons reduced these events by nearly half compared to uncoated balloons.
The balloon delivers sirolimus, an anti-proliferative drug, directly to the arterial wall during inflation. This drug prevents the overgrowth of cells that typically causes the vessel to narrow again after angioplasty.
No, the study reported no significant difference in death from any cause within one year between the sirolimus-coated and uncoated balloon groups, ensuring a high margin of safety.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Always seek the advice of a qualified healthcare provider for any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.
References
Barco S et al. Sirolimus-Coated Balloon Angioplasty for Infrainguinal Artery Disease. N Engl J Med. 2026 Mar 30. doi: 10.1056/NEJMoa2600360. PMID: 41911022.
American College of Cardiology. SirPAD: Sirolimus-Coated vs. Uncoated Balloons in Angioplasty For Infrainguinal Artery Disease. Late-Breaking Clinical Trial Session; 2026 Mar 30.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A large-scale trial confirms that sirolimus-coated balloon angioplasty significantly reduces major limb events in patients with infrainguinal artery disease...
3 months ago
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
